Dr. Reddy's Laboratories Limited to Present at the 36th Annual J.P. Morgan Healthcare Conference
January 06 2018 - 1:39AM
Business Wire
Dr. Reddy’s Laboratories Ltd (BSE: 500124)(NSE: DRREDDY)(NYSE:
RDY) announced that the Company will be presenting at the 36th
Annual J.P. Morgan Healthcare Conference in San Francisco,
California.
Alok Sonig, Executive Vice President and Head, North America
will present on Tuesday, January 9, 2018 at 2 p.m. (PST) [3:30 a.m.
IST on January 10, 2018].
Presentation material will be available on the Company’s website
www.drreddys.com.
Biographical Information:
Alok Sonig is Executive Vice President (Global) and Head of the
North America region for Dr. Reddy’s Laboratories. He is a member
of the Global Management Council for the corporation. Alok joined
Dr. Reddy’s in June 2012, running both the India-region in addition
to Global Business Development. During his tenure, the India
business delivered industry-leading growth and saw successful
acquisitions and integration of strategically important businesses.
Prior to joining Dr. Reddy’s, Sonig spent nearly 15 years at
Bristol-Myers Squibb, where he held several leadership positions in
general management, country leadership, global strategy and
marketing, mostly based in the U.S. His last role was Vice
President of Strategy in Princeton, New Jersey. Before joining
Bristol-Myers Squibb, Sonig was based in Washington, D.C., where he
spent several years as a management consultant working in various
industries on strategy and innovation assignments, including health
care, technology and telecommunications. Currently, he is a board
member of the Association for Accessible Medicine. He holds a
Bachelors of Engineering degree from Punjab Engineering College in
India, as well as a Masters in Business Administration from
American University in Washington, D.C. Sonig is married with two
daughters and lives in the Princeton, New Jersey, area.
About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE:
500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical
company, committed to providing affordable and innovative medicines
for healthier lives. Through its three businesses - Pharmaceutical
Services & Active Ingredients, Global Generics and Proprietary
Products – Dr. Reddy’s offers a portfolio of products and services
including APIs, custom pharmaceutical services, generics,
biosimilars and differentiated formulations. Our major therapeutic
areas of focus are gastrointestinal, cardiovascular, diabetology,
oncology, pain management and dermatology. Dr. Reddy’s operates in
markets across the globe. Our major markets include – USA, Russia
& CIS and India. For more information, log on to:
www.drreddys.com
Disclaimer: This press release may include statements of
future expectations and other forward-looking statements that are
based on the management’s current views and assumptions and involve
known or unknown risks and uncertainties that could cause actual
results, performance or events to differ materially from those
expressed or implied in such statements. In addition to statements
which are forward-looking by reason of context, the words "may",
"will", "should", "expects", "plans", "intends", "anticipates",
"believes", "estimates", "predicts", "potential", or "continue" and
similar expressions identify forward-looking statements. Actual
results, performance or events may differ materially from those in
such statements due to without limitation, (i) general economic
conditions such as performance of financial markets, credit
defaults , currency exchange rates , interest rates , persistency
levels and frequency / severity of insured loss events (ii)
mortality and morbidity levels and trends, (iii) changing levels of
competition and general competitive factors, (iv) changes in laws
and regulations and in the policies of central banks and/or
governments, (v) the impact of acquisitions or reorganization ,
including related integration issues.
The company assumes no obligation to update any information
contained herein.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180105005895/en/
DR. REDDY'S LABORATORIES LTD.INVESTOR
RELATIONSSAUNAK SAVLA,
+91-40-49002135saunaks@drreddys.comorMEDIA RELATIONSCALVIN
PRINTER, +91-40-49002121)calvinprinter@drreddys.com
Dr Reddys Laboratories (NYSE:RDY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Dr Reddys Laboratories (NYSE:RDY)
Historical Stock Chart
From Apr 2023 to Apr 2024